Decreased pretherapy serum apolipoprotein A-I is associated with extent of metastasis and poor prognosis of non-small-cell lung cancer

• Published in: OncoTargets and therapy Vol. 11; pp. 6995 - 7003
• Main Authors: Shi, Hui, Huang, Haidong, Pu, Jin, Shi, Dongchen, Ning, Yunye, Dong, Yuchao, Han, Yiping, Zarogoulidis, Paul, Bai, Chong
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.01.2018; Dove Medical Press
• Subjects: apolipoprotein A-I; Apolipoproteins; Atherosclerosis; Biomarkers; Breast cancer; Cancer therapies; Cholesterol; Esophagus; Hospitals; Laboratories; Lipids; Lipoproteins; Lung cancer; Medical prognosis; Metabolism; metastasis; Non-small cell lung carcinoma; NSCLC; Oncology; Original Research; Patients; prognosis; Proteins; Software; Survival analysis; United States > US; China; apolipoprotein A-I; NSCLC; metastasis; prognosis

Apolipoprotein A-I (ApoA-I), which recently attracted great attention as an important protein related to the increasing risk of various cancers, is a factor closely related to metabolic diseases such as ardiovascular diseases and atherosclerosis. However, the diagnostic and prognostic value of preth...